<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EMTRICITABINE</span><br/>(em-tri'ci-ta-been)<br/><span class="topboxtradename">Emtriva<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiretroviral</span>; <span class="classification">nucleoside reverse transcriptase inhibitor (nrti)</span><br/><b>Prototype: </b>Zidovudine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Emtricitabine is a synthetic nucleoside analogue with inhibitory activity against HIV. It inhibits HIV-1 reverse transcriptase
         (RT), both by competing with the natural DNA nucleoside and by incorporation into viral DNA, which terminates the formation
         of the viral DNA chain.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>The viral load is decreased as measured by an increase in CD4 leukocyte count and suppression of viral RNA.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of HIV in combination with other antiretroviral agents</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of chronic hepatitis B in HIV-positive patients</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety and efficacy in children and elderly are not established; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, and with end-stage renal disease; pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">HIV</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg once/d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 3049 mL/min: 200 mg q48h; 1529 mL/min: 200 mg q72h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at the same time daily.</li>
<li>Store between 15°30° C (59°86° F) in a tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, neuropathy, peripheral neuritis. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> depression, dizziness, insomnia. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea,</span> dyspepsia, abdominal pain, hepatomegaly. <span class="typehead">Metabolic:</span> Lactic acidosis. <span class="typehead">Musculoskeletal:</span> Arthralgia, myalgia, paresthesias. <span class="typehead">Respiratory:</span> Cough, rhinitis. <span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> hyperpigmentation of palms and soles of feet. 
      <h1><a name="interactions">Interactions</a></h1>None yet reported. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 93% reaches systemic circulation. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> 4% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Urine. <span class="typehead">Half-Life:</span> 10 h (active metabolite has intracellular half-life of 39 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>
            							Note: Persons with a detectable viral load to be switched from lamivudine to emtricitabine should have genotypic testing to determine
            whether the M184 mutation is present.
            						
         </li>
<li>Monitor closely for S&amp;S of lactic acidosis, especially in persons with known risk factors such as female gender, obesity,
            alcoholism, or hepatic disease.
         </li>
<li>Withhold drug and notify physician if S&amp;S suggestive of lactic acidosis or hepatotoxicity occur.</li>
<li>Lab tests: Baseline renal function tests; frequent LFTs and serum electrolytes during the last trimester of pregnancy; complete
            blood chemistry if lactic acidosis is suspected; and periodic lipid profile.
         </li>
<li>Monitor closely for severe exacerbation of hepatitis B in coinfected patients if this drug is discontinued.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Inform physician, prior to taking this drug, if you have used lamivudine and developed resistance to it.</li>
<li>Report any of the following to the physician: difficulty breathing, shortness of breath, fast or irregular heartbeat; weight
            gain with fullness around waist and/or face; vomiting or diarrhea; unexplained muscle aches, pains, weakness, or fatigue;
            yellow eyes or skin.
         </li>
<li>Avoid alcoholic drinks while taking this drug.</li>
<li>Do not self-treat nausea, vomiting, or stomach pain. Contact physician for guidance.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>